Integrating chemical and biological approaches to target NAD production and signaling in cancer ( INTEGRATA Project)

Innovamol is partner of the INTEGRATA consortium, which is an European Training Network (ETN) funded in the framework of the H2020 Marie Skłodowska- Curie ITN programme. The INTEGRATA network aims at the education of promising Early Stage Researchers (ESRs) who will learn the key steps of the modern discovery process of new drugs and therapeutic approaches focusing specifically on NAD production and on NAD/nucleotide signaling as targets for the development of new cancer therapeutics.

In vitro testing of new biologically active compounds

This project has received funding from the European Union’s Horizon 2020research and innovation programme under grant agreement No 813284

Consortium annual meeting

Molecular modelling and computer-aided drug design

Biological target evaluation and validation

Chemical library enumeration

Early-stage drug development in oncology

Innovamol collaborates with different academic and research centers with the aim to identify, synthesize, profile and evaluate new compounds with biological activity. Our major interest is related to targeted therapy in oncology and anticancer drug development

Characterising tobacco products

Tobacco products encompass hundreds of chemicals many of which are of health and safety concern. We are collaborating with EU Regulatory bodies to shape new and safe products (see  Independent Advisory Panel on characterising flavours in tobacco products)